

Sarcoma—rare, but not insignificant

This year, progress in treating rare cancers has been named the advance of the year by the American Society of Clinical Oncology (ASCO). Advancements in treating desmoid tumors, a subtype of sarcoma, was highlighted as one of the prominent breakthroughs for a rare cancer. While sarcoma is statistically rare, the impact of the disease is great, particularly on patients and families. ASCO’s recognition of rare cancer advancements demonstrates what the sarcoma community has long known: that “rare” shouldn’t mean unimportant or overlooked. In fact, the contributions of families, patients, caregivers, clinicians, researchers, foundations, organizations, and agencies in bringing sarcoma to the forefront and giving it prominence—spending time, effort, and energy in finding effective treatments—is of utmost importance, despite the disease’s rarity.

The Sarcoma Foundation of America (SFA) is leading the race to cure sarcoma,

and it is doing so through research, advocacy, and education. Since its founding in 2001, donors to the foundation have funded over \$9 million in research, with almost \$2 million to be invested in research projects this year alone. The SFA supports research focused on discovering and developing new and effective therapies to treat and eradicate sarcoma—often high-risk, high-reward projects that would not likely be funded by the government or commercial interests. Driving the research agenda are members of its Medical Advisory Board—some of the brightest scientific minds in the world today, several of whom also serve on the Editorial Advisory Board of this, the SFA’s official journal. We are thankful for their dedication. Together, their efforts will continue to make a difference in the lives of those impacted by sarcoma. **TSJ**

The Sarcoma Foundation of America
CureSarcoma.org

› ASCO’S RECOGNITION OF RARE CANCER ADVANCEMENTS DEMONSTRATES WHAT THE SARCOMA COMMUNITY HAS LONG KNOWN: THAT “RARE” SHOULDN’T MEAN UNIMPORTANT OR OVERLOOKED.

—The Sarcoma Foundation of America

EDITORIAL ADVISORY BOARD

EDITOR-IN-CHIEF

William D. Tap, MD

Chief, Medical Oncology Service
Memorial Sloan Kettering Cancer Center

MEMBERS

Mark Agulnik, MD

Lurie Comprehensive Cancer Center

John Charlson, MD

Medical College of Wisconsin

Anthony Conley, MD

MD Anderson Cancer Center

Charles Forscher, MD

Cedars-Sinai Medical Center

Abha Gupta, MD, MSc, FRCP

Hospital for Sick Children

Rick Haas, MD

Netherlands Cancer Institute

Andrea Hayes-Jordan, MD

University of North Carolina Children’s Hospital

David Kirsch, MD, PhD

Duke Health

Eugenie S. Kleinerman, MD

MD Anderson Cancer Center

Roberta Maestro, MD

Centro di Riferimento Oncologico (CRO)
National Cancer Institute

Paul A. Meyers, MD

Memorial Sloan Kettering Cancer Center

Scott Okuno, MD

Mayo Clinic

Raphael Pollock, MD, PhD

The Ohio State University Comprehensive Cancer Center

Damon Reed, MD

Moffitt Cancer Center

Richard Riedel, MD

Duke Health

Katherine A. Thornton, MD

Dana-Farber Cancer Institute